IL-MI-JACK
1.6.2022 17:12:06 CEST | Business Wire | Press release
Mi-Jack Products, the industry leader in Rubber Tired Gantry (RTG) Cranes, container handling machinery, and technology for port and intermodal facilities, has announced a successful acquisition of Yardeye GmbH, a Germany-based automation, collision avoidance, and work zone protection provider for the port and rail container industries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220601005458/en/
Yardeye’s RFID and GNSS-based equipment, personnel Real Time Locating System (RTLS), and Collision Avoidance System (CAS) fit seamlessly into Mi-Jack's Mi-Star® technology platform, which provides everything from differential GPS automated steering and GPS inventory management to virtualized operations view and centralized fleet management.
Combining both companies’ skilled and experienced technology groups into one will facilitate continued innovation and excellence for automation, collision avoidance, and work zone protection within ports and intermodal terminals.
Aaron Newton, VP of Sales for Mi-Jack, said, “By bringing these two similar but unique technology platforms together, the port and intermodal industries will now have an end-to-end automation solution with superior redundancy, led by a company [Mi-Jack] that’s been rooted in the container handling business for over 65 years.”
According to Simon Fiera, VP of Technology at Mi-Jack, “We see Yardeye as a key component of integrating into an agnostic crane manufacturing base for the purposes of automation and work zone protection. We look forward to the innovations and efficiencies that will come from combining the skillsets and experiences of both the European and North American technology teams.”
With this expanded footprint, Mi-Jack brings its world class support and service to Yardeye customers in North America and will provide Mi-Star technology solutions to ports and terminals across Europe. Mi-Jack provides 24/7/365 service and parts support and has a vast network of highly trained technicians and solutions experts that service customers both in-person and virtually.
Stephan Trauth, Managing Director of Yardeye, said, “We are very proud to join the Mi-Jack group. The know-how of both companies will generate more advanced capabilities and synergies. Together, we will provide an automation portfolio that sets new standards in the rail container industry. The network from Mi-Jack in the North American market and especially their competence will add more value and innovative ideas for our customers. We look forward to this new chapter!”
Christian Augustin, Founder of Yardeye and managing director of indurad said, “The team has been growing Yardeye since 2017 from a concept to a company with a global impact serving the intermodal and container handling industry. We are very proud with what we have achieved, and we believe that together with Mi-Jack, Yardeye will continue its success story, for our customers as well as our employees. indurad and I will continue to focus our activities on radar technology for bulk material handling.”
About Mi-Jack
Mi-Jack is recognized worldwide as an industry leader and innovator in rubber-tired gantry (RTG) cranes and other products and solutions globally. Mi-Jack's Mi-Star suite of automation technology includes AccuSteer , AccuStack , AccuView , VehicleView , and AccuFleet . Mi-Star is installed on thousands of pieces of equipment throughout the world.
Corporate headquarters are in Hazel Crest, Illinois at an ISO 9001:2017 certified facility that produces Translift™ and Travelift® RTG’s now in use on six continents. The company maintains four regional operations headquarters and five sales offices. Mi-Jack is part of the Lanco Group of Companies . For more information, go to www.mi-jack.com .
About Yardeye
Yardeye GmbH (www.yardeye.com ) operates internationally with a focus on port automation and work zone protection in container terminals. By Yardeye’s unique GNSS, RFID, and collisional avoidance technology, terminals are able to identify and track cranes, vehicles, and personnel for efficient intermodal yard operations and work zone protection.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220601005458/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom